Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

• Main Authors: Yu-Yang Liu (Author), Yi-Yang Qu (Author), Shang Wang (Author), Ci-Jun Luo (Author), Hong-Ling Qiu (Author), Hui-Ting Li (Author), Ping Yuan (Author), Lan Wang (Author), Jin-Ling Li (Author), Rong Jiang (Author), Rui Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Some patients treated with phosphodiesterase type 5 inhibitors (PDE-5is) fail to reach treatment goals. As a novel soluble guanylate cyclase agonist, riociguat acts on the same pathway as PDE-5is but functions via...